BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia.

BCMA-directed CAR T-cell therapy in 4 patients with refractory primary immune thrombocytopenia produced durable drug-free complete remission lasting up to 15 months.

• Why it matters: Refractory primary immune thrombocytopenia can persist despite existing treatments, creating a need for therapies that achieve sustained remission without ongoing drugs.
• What they did: In a clinical evaluation (NCT06519565), BCMA-directed CAR T cells were administered to 4 refractory patients, with safety monitoring and platelet response tracking over time.
• The result: The treatment showed manageable safety and rapid, sustained platelet recovery, enabling drug-free complete remission that persisted for up to 15 months.

AI summary of the abstract · may contain errors · not medical advice · read the paper.